Dr Charlotte Pawlyn speaks to ecancer about the findings from her study, a large-scale trial investigating treatment approaches for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplants.

The study compared outcomes of a quadruplet induction therapy of carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) against a triplet approach.

Key highlights include improved progression-free and overall survival for patients receiving the quadruplet therapy, as revealed through nearly a decade of follow-up.

The video also emphasises the role of proteasome inhibitors and immunomodulatory drugs in enhancing treatment outcomes and discusses the addition of anti-CD38 antibodies as part of evolving standards of care.

This presentation underscores the value of long-term follow-up in academic trials to capture meaningful survival data and the ongoing evolution of multiple myeloma treatment strategies.